1. Khosroshahi, A.G., M. Amanlou, O. Sabzevari, F.J. Daha and M.R. Aghasadeghi et al., 2013. A comparative study of two novel nanosized radiolabeled analogues of methionine for SPECT tumor imaging. Curr. Med. Chem., 20: 123-133.
   CrossRef  |  PubMed  |  
2. Zakeri, S., E. Afzal, P. Yaghmaei, M. Mirzaei and B. Mehravi et al., 2012. Nano-scaled diethylene triamine pent acetic acid (N-DTPA): Novel anti-Wilson's disease cell model. Am. J. Biomed. Sci., 4: 204-219.
   Direct Link  |  
3. Parasuraman, S., R. Raveendran, M.S. Ardestani,R. Ananthakrishnan and A. Jabbari-Arabzadeh et al., 2012. Biodistribution properties of cleistanthin A and cleistanthin B using magnetic resonance imaging in a normal and tumoric animal model. Pharmacogn. Mag., 8: 129-134.
   CrossRef  |  PubMed  |  Direct Link  |  
4. Adibkia, K., M. Alaei-Beirami, M. Barzegar-Jalali, G. Mohammadi and M.S. Ardestani, 2012. Evaluation and optimization of factors affecting novel diclofenac sodium-eudragit RS100 nanoparticles. Afr. J. Pharm. Pharmacol., 6: 941-947.
   CrossRef  |  Direct Link  |  
5. Fekrazad, R., N. Hakimiha, E. Farokhi, M.J. Rasaee, M.S. Ardestani, K.A.M. Kalhori and F. Sheikholeslami, 2011. Treatment of oral squamous cell carcinoma using anti-HER2 immunonanoshells. Int. J. Nanomed., 6: 2749-2755.
   CrossRef  |  Direct Link  |  
6. Ardestani, M.S., R.A. Cohan, A. Madadkar-Sobhani, H. Khanahmad and F. Roohvand et al., 2011. Design, modeling, expression, and chemoselective PEGylation of a new nanosize cysteine analog of erythropoietin. Int. J. Nanomed., 6: 1217-1227.
   PubMed  |  
7. Ardestani, M.S., A. Moshiri, S.M. Sadat, M.S. Ardestani, M. Hassan et al., 2011. Outer membrane vesicle of Neisseria meningitidis serogroup B as an adjuvant in immunization of rabbit against Neisseria meningitidis serogroup A. Afr. J. Microbiol. Res., 5: 3090-3095.
8. Amanlou, M., S.D. Siadat, S.E.S. Ebrahimi, A. Alavi and M.R. Aghasadeghi et al., 2011. Gd3+-DTPA-DG: Novel nanosized dual anticancer and molecular imaging agent. Int. J. Nanomed., 6: 747-763.
   Direct Link  |  
9. Amanlou, M., S.D. Siadat, D. Norouzian, M.R. Aghasadeghi, H.F. Moghaddam, M. Piryaei and M.S. Ardestani, 2011. Effect of dexamethasone on striatal neurotransmissions in the rats subjected to parkinson's disease animal model. Iran. J. Basic Med. Sci., 14: 107-115.
   Direct Link  |  
10. Aghasadeghi, M.R., G. Bahramali, S.M. Sadat, A. Farahani and M. Mohraz et al., 2011. Detection of hepatitis B virus variants in HBV monoinfected and HBV/HIV coinfected Iranian patients under lamivudine treatment. Cur. HIV Res., 9: 263-269.
    PubMed  |  
11. Zohri, M., M.S. Alavidjeh, I. Haririan, M.S. Ardestani, S.E.S. Ebrahimi, H.T. Sani and S.K. Sadjadi, 2010. A comparative study between the antibacterial effect of nisin and nisin-loaded chitosan/alginate nanoparticles on the growth of Staphylococcus aureus in raw and pasteurized milk samples. Probiotics Antimicrob. Proteins, 2: 258-266.
    CrossRef  |  
12. Moghaddam, H.F., M.J. Khodayar, S.M.Z. Abarghouei and M.S. Ardestani, 2010. Evaluation of the role of striatal cannabinoid CB₁ receptors on movement activity of parkinsonian rats induced by reserpinestar. Saudi Pharm. J., 18: 207-215.
    CrossRef  |  
13. Haririan, I., M.S. Alavidjeh, M.R. Khorramizadeh, M.S. Ardestani, Z.Z. Ghane and H. Namazi, 2010. Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines. Int. J. Nanomed., 5: 63-75.
    CrossRef  |  Direct Link  |  
14. Ebrahimi, S.E.S., M.S. Ardestani and M. Amanlou, 2010. Dose radiopharmaceutical science makes sense/over on MR contrast media agents or not? Curr. Radiopharmaceut., 3: 284-285.
    Direct Link  |  
15. Ardestani, M.S.,M. Amanlou, S.D. Siadat, D. Norouzian and S.E. Sadat-Ebrahimi et al ., 2010. Magnetic resonance contrast media sensing in vivo molecular imaging agents: An overview. Accepted Curr. Radiopharm., 4: 30-43.
    Direct Link  |  
16. Ardestani, M.S., M. Zohri, M. Alavidjeh, I. Haririan, S. Ebrahimi, H. Sani and S. Sadjadi, 2010. A comparative study between the antibacterial effect of nisin and nisin-loaded Chitosan/Alginate nanoparticles on the growth of staphylococcus aureus in raw and pasteurized milk samples. Probiotics Antimicrob. Pept., 2: 258-266.
    Direct Link  |  
17. Ardestani, M.S., I. Haririan, M.R. Khorramizadeh, Z.Z. Ghane, M.S. Ardestani and H. Namazi, 2010. Anionic linear-globular dendrimers: Biocompatible hybrid materials with potential uses in nanomedicine. J. Mater. Sci. Mater. Med., 21: 1121-1133.
    CrossRef  |  
18. Ardestani, M.S., H. Fathi-Moghaddama, M. Saffaric, A. Jabbari, Arabzadeh and M. Elmi, 2010. The selective cyclooxygenase-2 inhibitor, the compound 11b improves haloperidol induced catatonia by enhancing the striatum dopaminergic neurotransmission. Accepted Iran. J. Pharm. Res., 9: 387-393.
    Direct Link  |  
19. Ardestani, M.S., D.N. Inanlou, B. Yakhchali, H. Khanahmad and M. Gardaneh et al., 2010. Towards β-globin gene-targeting with integrase-defective lentiviral vectors. Biotech. Lett., 32: 1615-1621.
    CrossRef  |  
20. Ardestani, M.S., A.A. Jabbari, H. Zahra, H. Amirreza and E. Hamidreza et al., 2010. Novel and facile methods for the synthesis of DTPA- mono-amide: A new completely revised strategy in Radiopharmaceutical Chemistry. J. Radioanal. Nucl. Chem., 283: 447-455.
    Direct Link  |  
21. Ardestani, M.S., 2010. Potential opponent for 18FDG: Gd3+-DTPA-DG: A new synthetic MRI contrast agent. Iran. J. Radiol., 7: 56-56.
    Direct Link  |  
22. Ardestani, M.S., 2010. Parkinsons disease, the inflammatory pathway and anti-inflammatory drugs: An overview. J. Med. Sci., 10: 49-58.
    CrossRef  |  Direct Link  |  
23. Ardestani, M.S., 2010. Novel mri radiopharmaceuticals suggested for molecular imaging. Pharm. Global., 1: 1-4.
    Direct Link  |  
24. Moghaddam, H.F., M.S. Ardestani, M. Saffari, L. Navidpour, A. Shafiee and A. Rahmim, 2008. Dopaminergic but not glutamatergic neurotransmission is increased in the striatum after selective Cyclooxygenase-2 inhibition in normal and hemiparkinsonian rats. Basic Clin. Pharm. Toxicol., 103: 293-296.
    CrossRef  |  Direct Link  |  
25. Moghaddam, H.F. and M.S. Ardestani, 2008. Electrical lesion of substantia nigra pars compacta: An alternative and convenient way to generate the animal model of parkinsons disease. Iran. J. Pharmacol. Therapeutics, 7: 53-56.
    Direct Link  |  
26. Fathi-Moghaddam, H., M.S. Ardestani, M.S. Ardestani, D. Barzegar-Pourshuraki, A. Gravand, L. Navidpour, H. Ebrahiminik and A. Shafiee, 2008. COX inhibition: Catalepsy and striatum Dopaminergic-GABAergic-glutamatergic neurotransmission. Nat. Preced., 10101/npre.2008.1481.1.
    CrossRef  |  
27. Ardestani, S.M., M. Saffari and M. Shahbazi, 2008. Formulation and in vitro Evaluation of Eudragit L100 piroxicam. Nat. Preced., 10.1038/npre.2008.1544.1.
    CrossRef  |  
28. Ardestani, M.S., M. Saffary, H.F. Moghaddam, A. Hemmati, L. Navidpour and A. Shafiee, 2008. P4-328: Effects of COX-2 and COX-2 gene expression inhibitors on memory-movement disorders and hippocampus-striatal cholinergic and glutamatergic neurotransmission. Alzheimer. Dementia J. Alzheimer. Assoc., 4: T768-T769.
    CrossRef  |  Direct Link  |  
29. Ardestani, M.S., H.F. Moghaddam, A.A. Hemmati and Z. Nazari, 2008. Effect of Cyclooxygenase-2 inhibition on rigidity of animal model of Parkinson's disease. Tehran Univ. Med. J., 66: 309-314.
    Direct Link  |  
30. Ardestani, M.S., H.F. Moghaddam and M. Saffari, 2008. Effect of compound 11g as a novel selective cox-2 inhibitor on movement disorders in a rat model of Parkinson's disease. Pak. J. Med. Sci., 24: 436-441.
    Direct Link  |  
31. Ardestani, M.S., H. Mehrab, A. Geravand, N. Mohajer and M. Saffari, 2008. Steroidal anti inflammatory drug betamethasone significantly alters level of striatal dopamine in a rat model of Parkinson's disease. Nat. Prec. .
    Direct Link  |  
32. Ardestani, M.S., 2008. Effect of Cyclooxygenase-2 inhibition on rigidity of animal model of Parkinson's disease. Tehran Uni. Med. J., 66: 299-304.
    Direct Link  |  
33. Ardestani, M.S. and H. Fathi-Moghaddam, 2008. COX inhibition: Catalepsy and striatum dopaminergic-GABaergic-glutamatergic neurotransmission. Nat. Prec. .
    Direct Link  |  
34. Ardestani, M.S. and H. Fathi-Moghaddam, 2008. Betamethasone can significantly decrease level of striatal glutamate in animal model of parkinson's disease. Iran. J. Pharma. Res., 7: 229-232.
    Direct Link  |  
35. Moghaddam, H.F., A. Hemmati, Z. Nazari, H. Mehrab, K.M. Abid and M.S. Ardestani, 2007. Effects of aspirin and celecoxib on rigidity in a rat model of Parkinson's disease. Pak. J. Biol. Sci., 10: 3853-3858.
    CrossRef  |  PubMed  |  Direct Link  |  
36. Ardestani, M.S., H. Mehrab and N. Sadeghzadeh, 2007. Effects of dexamethasone and betamethasone as COX-2 gene expression inhibitors on rigidity in a rat model of Parkinson's disease. Indian. J. Pharmacol., 39: 235-239.
    Direct Link  |